Bragar Eagel & Squire, P.C. Is Investigating Oak Street Health, Hollysys Automation, and Cronos Group and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Oak Street Health, Inc. (NYSE: OSH), Hollysys Automation Technologies Ltd. (NASDAQ: HOLI), and Cronos Group, Inc. (NASDAQ: CRON). Our investigations concern whether these companies have violated the federal securities laws andor engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

Oak Street Health, Inc. (NYSE: OSH)

In Oak Street's Q3 update on Monday, November 8, 2021, the Company revealed that the U.S. Department of Justice (DOJ) is investigating whether it may have violated the False Claims Act and said the DOJ has requested documents and information related to Oak Street providing free transportation to federal healthcare beneficiaries and related to its relationships with third-party marketing agents.

On this news, Oak Street's stock price fell $9.75 per share, or 20%, to close at $37.14 on November 9, 2021, thereby injuring investors.

For more information on the Oak Street Health investigation go to: https://bespc.com/cases/OSH

Hollysys Automation Technologies Ltd. (NASDAQ: HOLI)

On November 2, 2021, Hollysys filed a notice with the U.S. Securities and Exchange Commission stating that the Company could not timely file its annual report for the period ended June 30, 2021 because of a "delay in collecting supporting documents and information." Hollysys also disclosed that it had replaced Ernst & Young Hua Ming LLP as its independent auditor.

On this news, Hollysys's stock price fell $5.69 per share, or 29%, to close at $13.70 per share on November 3, 2021.

For more information on the Hollysys Automation investigation go to: https://bespc.com/cases/HOLI

Cronos Group, Inc. (NASDAQ: CRON)

On November 9, 2021, Cronos filed a Form 8-K with the U.S. Securities and Exchange Commission, stating that "[o]n November 8, 2021, Cronos Group Inc. . . . determined that it will be required to restate its previously issued unaudited interim financial statements for the three and six months ended June 30, 2021 previously filed on Form 10-Q on August 6, 2021" and advising that "[t]he Company's financial statements for this period should therefore no longer be relied upon." Cronos further stated that "[t]he Company concluded that it should have recorded an impairment charge of not less than $220 million on goodwill and indefinite-lived intangible assets in its U.S. reporting unit for the three and six months ended June 30, 2021. The Company will restate its unaudited interim financial statements for the three and six months ended June 30, 2021, accordingly." According to Cronos, the Company "is also evaluating whether to record an additional impairment in the three and nine months ended September 30, 2021."

On this news, Cronos's stock price fell $1.01 per share, or 15.05%, to close at $5.70 per share on November 9, 2021.

For more information on the Cronos Group investigation go to: https://bespc.com/cases/CRON

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com . Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

CRON:CA,CRON
The Conversation (0)
Cannabis leaf.

10 Biggest Cannabis Stocks in the US and Canada in 2026

After a year of stop‑start policy signals, the US cannabis market ended 2025 with a new wave of attention as US President Donald Trump moved to accelerate federal cannabis rescheduling efforts. His December executive order directing the attorney general to complete the process of shifting... Keep Reading...
Cannabis business with marijuana leaves and stock

Cannabis Market 2025 Year-End Review

2025 marked a turning point for investment in the cannabis sector, shifting the focus toward operational resilience and consolidation after a sluggish 2024. Key market drivers included an upswing in merger and acquisition (M&A) activity as stronger multi-state operators (MSOs) acquired... Keep Reading...
Cannabis plant with green leaves and buds on a dark green background.

Cannabis Market Forecast: Top Trends for Cannabis in 2026

The US cannabis market is entering 2026 with brighter prospects after a punishing few years marked by stalled rescheduling efforts, price compression, retail saturation and slow state expansion.Now, however, regulatory tailwinds seeming aligned for a potential re-rating.On December 18, US... Keep Reading...
Cannabis plant in focus, blurred US flag background.

Analysts React: Trump Signs Executive Order to Reschedule Cannabis

The long-debated issue of US cannabis rescheduling is finally back in the spotlight. On Thursday (December 18), President Donald Trump signed an executive order to expedite the process of moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. Market watchers are now... Keep Reading...
Close-up of green cannabis leaves in natural light.

Trump Weighs Executive Order to Loosen Federal Cannabis Restrictions

US President Donald Trump is reportedly weighing a major shift in federal drug policy that would relax decades-old restrictions on cannabis, potentially injecting new life into the industry. Six people familiar with the discussions told the Washington Post that Trump is preparing an executive... Keep Reading...
Gavel on a surface with scattered cannabis leaves, symbolizing legal issues around marijuana.

Hemp THC Recriminalization: A Blow to a Blooming Industry

A spending bill to reopen the US government after a 43 day shutdown includes provisions that will recriminalize most hemp-derived THC products. This change, slated to become effective one year after enactment, in late 2026, marks a significant policy reversal from the 2018 Farm Bill, which... Keep Reading...

Interactive Chart

Latest Press Releases

Related News